Last reviewed · How we verify
Geptanolimab Injection 280mg, q3w
At a glance
| Generic name | Geptanolimab Injection 280mg, q3w |
|---|---|
| Also known as | Recombinant PD-1 humanized monoclonal antibody injection, Geptanolimab Injection |
| Sponsor | Genor Biopharma Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Geptanolimab Injection 280mg, q3w CI brief — competitive landscape report
- Geptanolimab Injection 280mg, q3w updates RSS · CI watch RSS
- Genor Biopharma Co., Ltd. portfolio CI